Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Merck announces data from ZOSTAVAX Phase III study on shingles

Merck, known as MSD outside the United States and Canada, announced today that data from the pivotal Phase III study with ZOSTAVAX(Zoster Vaccine Live) in adults ages 50 to 59 were published in the April 1 issue of Clinical Infectious Diseases.

3 Apr 2012

PolyTherics, Spirogen enter research collaboration to produce novel ADCs for treatment of cancer

PolyTherics Limited, a provider of solutions to enable the development of better biopharmaceuticals, and Spirogen Limited, a leading oncology-focused company developing DNA sequence-targeted agents, announce that they have formed a research collaboration to develop antibody drug conjugates that combine PolyTherics' proprietary site-specific conjugation chemistry with Spirogen's highly potent novel cytotoxic drugs to produce novel ADCs for the treatment of cancer.

2 Apr 2012

Safe method for destroying cancer cells using death cap mushroom poison

The mere thought of an identification error sends a chill down the spine of any mushroom lover: The death cap mushroom (Amanita phalloides), which resembles the common white button mushroom, contains one of the most deadly poisons found in nature, α-amanitin.

2 Apr 2012

Rare T follicular helper cells essential for developing antibody responses to infectious agents

The characterisation of a rare immune cell's involvement in antibody production and ability to 'remember' infectious agents could help to improve vaccination and lead to new treatments for immune disorders, say researchers from the Walter and Eliza Hall Institute.

2 Apr 2012

Study confirms link between breast cancer and autoimmune arthritis

New research shows it may be no accident when doctors observe how patients suffering from both breast cancer and arthritis seem to have more aggressive cancer. However, the new-found interaction between the two diseases may also suggest a possible treatment.

2 Apr 2012

Combination of cixutumumab and temsirolimus shrinks tumors in patients with Ewing's sarcoma

A pair of targeted therapies shrank tumors in some patients with treatment-resistant Ewing's sarcoma or desmoplastic small-round-cell tumors, according to research led by investigators from The University of Texas MD Anderson Cancer Center reported at the AACR Annual Meeting 2012.

2 Apr 2012

Dyax, GE Healthcare partner to develop and commercialize c-Met imaging peptides

GE Healthcare, a unit of GE, and Dyax Corp. today announced a licensing agreement for the development and commercialization of peptides binding to c-Met, which provides upfront, milestone, and royalty payments to Dyax.

2 Apr 2012

Nasal spray to prevent fat and plaque built up in the heart on the horizon

Researchers found a treatment that was much more effective in removing fat from arteries than established methods. The vaccine can be given as an injection or in a slightly different form as a nasal spray. A trial on 144 heart disease sufferers is under way in the US and Canada.

1 Apr 2012

Rare immune cells found to play a major role in lasting immunity

According to the latest research from the Walter and Eliza Hall Institute the characterization of a rare immune cell’s involvement in antibody production and ability to ‘remember’ infectious agents could help to improve vaccination and lead to new treatments for immune disorders.

1 Apr 2012

ImmunoGen commences IMGN901 Phase II evaluation for SCLC

ImmunoGen, Inc. today announced that it has initiated Phase II testing of its IMGN901 product candidate for first-line treatment of SCLC.

31 Mar 2012

ChemoCentryx fourth quarter revenues increase to $26.1 million

ChemoCentryx, Inc. announced today its financial results for the fourth quarter and year ended December 31, 2011.

31 Mar 2012

Women with HIV superinfection have more potent antibody responses

Women who have been infected by two different strains of HIV from two different sexual partners - a condition known as HIV superinfection - have more potent antibody responses that block the replication of the virus compared to women who've only been infected once. These findings, by researchers at Fred Hutchinson Cancer Research Center in Seattle, are published online March 29 in PLoS Pathogens.

30 Mar 2012

Positive results from Genentech's T-DM1 Phase III trial on HER2-positive mBC

ImmunoGen, Inc., a biotechnology company that develops anticancer products using its Targeted Antibody Payload (TAP) technology, today announced that Roche has announced positive topline results from its trastuzumab emtansine (T-DM1) EMILIA Phase III trial.

30 Mar 2012

Lilly's ixekizumab Phase II trial on plaque psoriasis meets primary endpoint

New Phase II data, published today in the New England Journal of Medicine, showed that Eli Lilly and Company's ixekizumab, an anti-IL-17 monoclonal antibody, met its primary endpoint in patients with moderate-to-severe plaque psoriasis, with significantly more patients achieving at least a 75 percent improvement in Psoriasis Area and Severity Index (PASI) scores from baseline (PASI 75) compared with placebo at week 12.

29 Mar 2012

MabCure retains CUNY CAT to evaluate monoclonal antibodies against ovarian cancer

MabCure Inc., a leading developer of antibody-based technology for the diagnosis and treatment of ovarian, prostate, colorectal and other cancers, has retained the CUNY Center for Advanced Technology (CUNY CAT) to evaluate its monoclonal antibodies against ovarian cancer cells as diagnostic reagents.

29 Mar 2012

NEJM publishes results from Amgen's brodalumab Phase 2 trial on plaque psoriasis

Amgen announced today that results from a Phase 2 trial evaluating the safety and efficacy of brodalumab in 198 patients with moderate to severe plaque psoriasis were published in the New England Journal of Medicine.

29 Mar 2012

Potential new therapy that kills cancer cells selectively

Researchers have made a drug that helps the immune system to break down cancerous tumors. It has worked on breast, bowel, prostate, ovarian, brain, bladder and liver cancers, while previous studies show it can also be used to fight some blood cancers. If given early, the drug could even be a cure, researchers say.

28 Mar 2012

Experimental drugs from Sanofi and Regenron cut cholesterol in a new way

An experimental drug that acts in a novel way to lower cholesterol proved even more effective than statins and had few undesirable side effects, newly released data shows. The drug acts by modifying the way cholesterol levels are naturally controlled. A protein produced in the liver helps limit the amount of LDL, or “bad” cholesterol, that liver cells can remove from the bloodstream. The new drug, called REGN727, is a monoclonal antibody, made in a laboratory, that blocks the action of that protein.

27 Mar 2012

Pfizer to present data on ADCs at AACR 2012

Pfizer Oncology will present data from a variety of preclinical and clinical studies of Pfizer's early-stage compounds, including data from Pfizer's investigational antibody-drug conjugate (ADC) portfolio and research evaluating several molecules targeting novel pathways that play a crucial role in basic cellular functions, at the American Association for Cancer Research (AACR) Annual Meeting 2012 in Chicago, IL, from March 31-April 4.

27 Mar 2012

SAR236553/REGN727 antibody reduces LDL by up to 72% in patients

A novel monoclonal antibody identified in a new study dramatically lowered circulating LDL cholesterol by 40 percent to 72 percent, a development with potential to provide a new option for patients who are resistant to cholesterol-lowering drugs such as statins or to the current standard of care, according to research presented today at the American College of Cardiology's 61st Annual Scientific Session.

27 Mar 2012